Textbook of Clinical Management of Club Drugs and Novel Psychoactive Substances NEPTUNE Clinical Guidance
Book contents
- Textbook of Clinical Management of Club Drugs and Novel Psychoactive Substances
- Textbook of Clinical Management of Club Drugs and Novel Psychoactive Substances
- Copyright page
- Contents
- Acknowledgements
- Part I Introduction and Background
- Part II Drugs with Primarily Depressant Effects
- Part III Drugs with Primarily Stimulant Effects
- Chapter 8A Introduction to Stimulant Club Drugs and Novel Psychoactive Substances
- Chapter 8B Amphetamine-type Stimulants: An Overview
- Chapter 9 ‘Ecstasy’: MDMA (3,4-Methylenedioxy-N-Methylamphetamine), MDMA Analogues and Drugs with Similar Effects
- Chapter 10 Methamphetamine
- Chapter 11 Synthetic Cathinones
- Part IV Drugs with Primarily Hallucinogenic Effects
- Part V Synthetic Cannabinoid Receptor Agonists
- Part VI Concluding Remarks
- Index
- References
Chapter 11 - Synthetic Cathinones
from Part III - Drugs with Primarily Stimulant Effects
Published online by Cambridge University Press: 06 October 2022
Book contents
- Textbook of Clinical Management of Club Drugs and Novel Psychoactive Substances
- Textbook of Clinical Management of Club Drugs and Novel Psychoactive Substances
- Copyright page
- Contents
- Acknowledgements
- Part I Introduction and Background
- Part II Drugs with Primarily Depressant Effects
- Part III Drugs with Primarily Stimulant Effects
- Chapter 8A Introduction to Stimulant Club Drugs and Novel Psychoactive Substances
- Chapter 8B Amphetamine-type Stimulants: An Overview
- Chapter 9 ‘Ecstasy’: MDMA (3,4-Methylenedioxy-N-Methylamphetamine), MDMA Analogues and Drugs with Similar Effects
- Chapter 10 Methamphetamine
- Chapter 11 Synthetic Cathinones
- Part IV Drugs with Primarily Hallucinogenic Effects
- Part V Synthetic Cannabinoid Receptor Agonists
- Part VI Concluding Remarks
- Index
- References
Summary
The natural analogue to synthetic cathinones is the active compound in the leaves of the khat plant (Catha edulis), which have been chewed for centuries in parts of Africa and the Arabian Peninsula for their stimulant properties.1 Synthetic cathinones are also prescribed medications, such as bupropion, Wellbutrin®.
- Type
- Chapter
- Information
- Textbook of Clinical Management of Club Drugs and Novel Psychoactive SubstancesNEPTUNE Clinical Guidance, pp. 240 - 266Publisher: Cambridge University PressPrint publication year: 2022
References
Warfa, N, Klein, A, Bhui, K, Leavey, G, Craig, T, Alfred Stansfeld, S. Khat use and mental illness: a critical review. Soc Sci Med 2007;65(2):309–318.Google Scholar
World Drug Report 2019 (United Nations publication, Sales No. E.19.XI.9)Google Scholar
World Drug Report 2020 (United Nations publication, Sales No. E.20.XI.6).Google Scholar
European Monitoring Centre for Drugs and Drug Addiction and Europol. EU Drug Markets Report 2019. Luxembourg, Publications Office of the European Union, 2019.Google Scholar
European Monitoring Centre for Drugs and Drug Addiction. European Drug Report 2020: Trends and Developments. Luxembourg, Publications Office of the European Union, 2020.Google Scholar
European Monitoring Centre for Drugs and Drug Addiction and Europol. EU Drug Markets Report 2019. Luxembourg, Publications Office of the European Union, 2019.Google Scholar
Lopez-Rodriguez, AB, Viveros M-P., Bath salts and polyconsumption: in search of drug-drug interactions. Psychopharmacology 2019;236:1001–1014. https://doi.org/10.1007/s00213-019-05213-3Google Scholar
Corkery, JM, Guirguis, A, Papanti, DG, Orsolini, L, Schifano, F. Synthetic cathinones: prevalence and motivations for use. In: J Zawilska, (ed.), Synthetic Cathinones. Current Topics in Neurotoxicity, volume 12. Cham, Springer.Google Scholar
Baumann, MH, Volkow, ND. Abuse of new psychoactive substances (NPS): threats and solutions. Neuropsychopharmacology 2016;41(3):663–665. https://doi.org/10.1038/npp.2015.260Google Scholar
Baumann, MH, Ayestas, MA Jr, Partilla, JS, et al. The designer methcathinone analogs, mephedrone and methylone, are substrates for monoamine transporters in brain tissue. Neuropsychopharmacology 2012;37:1192–1203. https://doi.org/10.1038/npp.2011.304Google Scholar
Javadi-Paydar, M, Nguyen, JD, Vandewater, SA, Dickerson, TJ, Taffe, MA. Locomotor and reinforcing effects of pentedrone, pentylone and methylone in rats.
Neuropharmacology 2018;134(Pt A):57–64. https://doi.org/10.1016/j.neuropharm.2017.09.002Google Scholar
Valente, MJ, Guedes de Pinho, P, de Lourdes Bastos, M, Carvalho, F, Carvalho, M. Khat and synthetic cathinones: a review. Arch Toxicol 2014;88(1):15–45. https://doi.org/10.1007/s00204-013-1163-9Google Scholar
Beck, O, Helander, A, Signell, P, Backberg M. Intoxications in the STRIDA project involving a panorama of psychostimulant pyrovalerone derivatives, MDPV. Clin Toxicol 2018;56(4);256–263.https://doi.org/10.1080/15563650.2017.1370097Google Scholar
Valente, MJ, Guedes de Pinho, P, de Lourdes Bastos, M, Carvalho, F, Carvalho, M. Khat and synthetic cathinones: a review. Arch Toxicol 2014;88(1):15–45. https://doi.org/10.1007/s00204-013-1163-9Google Scholar
Qian Z, , Jia W, Li T, Liu, C, Hua Z., Drug identification and analytical characterization of four synthetic cathinone derivatives iso-4-BMC, β-TH-naphyrone, mexedrone, and 4-MDMC test. Analysis 2017;9:274–281.Google Scholar
Sande M. Characteristics of the use of 3-MMC and other new psychoactive drugs in Slovenia, and the perceived problems experienced by users. Int J Drug Policy 2016;27:65–73.CrossRefGoogle Scholar
Mecham, F, Measham, F, Moore, K, Mephedrone, Østergaard J, ‘Bubble’ and unidentified white powders: the contested identities of synthetic ‘legal highs’. Drugs Alcohol Today 2011;11(3):137–146.Google Scholar
Péterfi A, Tarján A, Csaba Horváth G, Csesztregi T, Nyírádya A. Changes in patterns of injecting drug use in Hungary: a shift to synthetic cathinones. Drug Test Analysis 2014 (online. https://doi.org/10.1002/dta.1625Google Scholar
Corkery, JM, Guirguis, A, Papanti, DG, Orsolini, L, Schifano, F. Synthetic cathinones: prevalence and motivations for use. In: Zawilska, J (ed.), Synthetic Cathinones. Current Topics in Neurotoxicity, volume 12. Cham, Springer.Google Scholar
Baumann, MH, Partilla, JS, Lehner, KR, et al. Powerful cocaine-like actions of 3,4-methylenedioxypyrovalerone (MDPV), a principal constituent of psychoactive ‘bath salts’ products. Neuropsychopharmacology 2013;38:552–562. https://doi.org/10.1038/npp.2012.204Google Scholar
United Nations Office on Drugs and Crime (UNODC), Laboratory and Scientific Section. Details for Synthetic Cathinones. Available at: www.unodc.org/LSS/SubstanceGroup/Details/67b1ba69-1253-4ae9-bd93-fed1ae8e6802 [last accessed 16 March 2022].Google Scholar
Fleckenstein, AE, Volz, TJ, Riddle, EL, Gibb, JW, Hanson, GR. New insights into the mechanism of action of amphetamines. Annu Rev Pharmacol Toxicol 2007;47:681–698.Google Scholar
Cozzi, NV, Sievert, MK, Shulgin, AT, Jacob, P 3rd, Ruoho, AE. Inhibition of plasma membrane monoamine transporters by beta-ketoamphetamines. Eur J Pharmacol 1999;381(1):63–69.Google Scholar
Coppola, M, Mondola, R. Synthetic cathinones: chemistry, pharmacology and toxicology of a new class of designer drugs of abuse marketed as ‘bath salts’ or ‘plant food’. Toxicol Lett 2012;211(2):144–149. https://doi.org/10.1016/j.toxlet.2012.03.009Google Scholar
Baumann, MH, Partilla JS, , Lehner KR, . Psychoactive ‘bath salts’: Not so soothing. Eur J Pharmacol 2013;698:1–5. https://doi.org/10.1016/j. ejphar.2012.11.020Google Scholar
Luethi, D, Liechti, ME. Monoamine transporter and receptor interaction profiles in vitro predict reported human doses of novel psychoactive stimulants and psychedelics. Int J Neuropsychopharmacol 2018;21:926–931.Google Scholar
Lopez-Rodriguez, AB, Viveros, MP. Bath salts and polyconsumption: in search of drug-drug interactions. Psychopharmacology 2019;236:1001–1014. https://doi.org/10.1007/s00213-019-05213-3Google Scholar
Glennon, RA, Dukat, M. Synthetic cathinones: a brief overview of overviews with applications to the forensic sciences. Ann Forensic Res Anal 2017;4(2):1040.Google Scholar
Lopez-Rodriguez AB, , Viveros M-P. Bath salts and polyconsumption: in search of drug-drug interactions. Psychopharmacology 2019;236:1001–1014. https://doi.org/10.1007/s00213-019-05213-3CrossRefGoogle ScholarPubMed
Guirguis A, , Corkery JM, , Stair JL, , Kirton SB, , Zloh M, , Schifano F., Intended and unintended use of cathinone mixtures. Hum Psychopharmacol Clin Exp 2017;32:e2598. https://doi.org/10.1002/hup.2598Google Scholar
Simmler, TA, Buser Donzelli, M et al., Y Pharmacological characterization of designer cathinones in vitro. Br J Pharmacol 2013;168:458–470.CrossRefGoogle ScholarPubMed
Schifano, F, Papanti, GD, Orsolini, L, Corkery, JM. Novel psychoactive substances: the pharmacology of stimulants and hallucinogens. Exp Rev Clin Pharmacol 2016;9(7):943–954.CrossRefGoogle ScholarPubMed
Carroll, FI, Lewin, AH, Mascarella, SW, Seltzman, HH, Reddy, PA. Designer drugs: a medicinal chemistry perspective. Ann NY Acad Sci 2012;1248:18–38.Google Scholar
Iversen, L, White, M, Treble, R. Designer psychostimulants: pharmacology and differences. Neuropharmacology 2014;87:59–65. https://doi.org/10.1016/j.neuropharm.2014.01.015Google Scholar
Hadlock, GC, Webb, KM, McFadden, LM, et al. 4-Methylmethcathinone (mephedrone): neuropharmacological effects of a designer stimulant of abuse. J Pharmacol Exp Ther 2011;339(2):530–536. https://doi.org/10.1124/jpet.111.184119Google Scholar
Baumann MH, Partilla JS, Lehner KR, et al. Powerful cocaine-like actions of 3,4-Methylenedioxypyrovalerone (MDPV), a principal constituent of psychoactive ‘bath salts’ products. Neuropsychopharmacology 2013;38(4):552–562.Google Scholar
Baumann, MH, Partilla, JS, Lehner, KR, et al. Powerful cocaine-like actions of 3,4-methylenedioxypyrovalerone (MDPV), a principal constituent of psychoactive ‘bath salts’ products. Neuropsychopharmacology 2013;38(4):552–562.Google Scholar
López-Arnau, R, Buenrostro-Jáuregui, M, Camarasa, J, et al. Effect of the combination of mephedrone plus ethanol on serotonin and dopamine release in the nucleus accumbens and medial prefrontal cortex of awake rats. Naunyn Schmiedebergs Arch Pharmacol 2018;391:247–254. https://doi.org/10.1007/s00210-018-1464-xGoogle Scholar
Baumann, MH, Partilla, JS, Lehner, KR, et al. Powerful cocaine-like actions of 3,4-methylenedioxypyrovalerone (MDPV), a principal constituent of psychoactive ‘bath salts’ products. Neuropsychopharmacology 2013;38:552–562. https://doi.org/10.1038/npp.2012.204Google Scholar
Baumann, MH, Partilla, JS, Lehner, KR, et al. Powerful cocaine-like actions of 3,4-methylenedioxypyrovalerone (MDPV), a principal constituent of psychoactive ‘bath salts’ products. Neuropsychopharmacology 2013;38:552–562. https://doi.org/10.1038/npp.2012.204Google Scholar
Simmler, LD, Buser, TA, Donzelli, M, et al. Pharmacological characterization of designer cathinones in vitro. Br J Pharmacol 2013;168 :458–470.Google Scholar
Cameron K, , Kolanos R, , Verkariya R, , De Felice L, , Glennon RA., Mephedrone and Methylenedioxypyrovalerone (MDPV), major constituents of bath salts, produce opposite effects at the human dopamine transporter. Psychopharmacology 2013;227(3):493–499. https://doi.org/10.1007/s00213-013-2967-2Google Scholar
Glennon, RA, Dukat, M. Synthetic cathinones: a brief overview of overviews with applications to the forensic sciences. Ann Forensic Res Anal 2017;4(2):1040.Google Scholar
Advisory Council on the Misuse of Drugs (ACMD). Consideration of the Cathinones. London, Home Office, 2010.Google Scholar
Beck O, , Bäckberg M, , Signell P, , Helander A., Intoxications in the STRIDA project involving a panorama of psychostimulant pyrovalerone derivatives: MDPV copycats. Clin Toxicol 2018;56(4):256–263. https://doi.org/10.1080/15563650.2017.1370097Google Scholar
Meltzer, PC, Butler, D, Deschamps, JR, et al. 1-(4-Methylphenyl)-2- pyrrolidin-1-yl-pentan-1-one (Pyrovalerone) analogues: a promising class of monoamine uptake inhibitors. J Med Chem 2006;49:1420–1432.Google Scholar
Beck O, , Bäckberg M, , Signell P, , Helander A., Intoxications in the STRIDA project involving a panorama of psychostimulant pyrovalerone derivatives: MDPV copycats. Clin Toxicol 2018;56(4):256–263. https://doi.org/10.1080/15563650.2017.1370097Google Scholar
Meltzer, PC, Butler, D, Deschamps, JR, et al. 1-(4-Methylphenyl)-2- pyrrolidin-1-yl-pentan-1-one (Pyrovalerone) analogues: a promising class of monoamine uptake inhibitors. J Med Chem 2006;49:1420–1432.Google Scholar
Gardos, G, Cole, JO. Evaluation of pyrovalerone in chronically fatigued volunteers. Curr Ther Res Clin Exp 1971;13:631–635.Google Scholar
Fung, M, Thornton, A, Mybeck, K, et al. Evaluation of the characteristics of safety withdrawal of prescription drugs from worldwide pharmaceutical markets – 1960 to 1999. Drug Inf J 2001;35:293–317.Google Scholar
World Health Organization. Convention on psychotropic substances, 1971. Available at: www.who.int/data/gho/indicator-metadata-registry/imr-details/3384 [last accessed 26 April 2022].Google Scholar
European Monitoring Centre for Drugs and Drug Addiction and Europol. EU Drug Markets Report 2019. Luxembourg, Publications Office of the European Union, 2019.Google Scholar
World Drug Report 2019 (United Nations publication, Sales No. E.19.XI.9).Google Scholar
European Monitoring Centre for Drugs and Drug Addiction. European Drug Report 2020: Trends and Developments. Luxembourg, Publications Office of the European Union, 2020.Google Scholar
Measham, F, Moore, K, Newcombe, R, Welch, Z. Tweaking, bombing, dabbing and stockpiling: the emergence of mephedrone and the perversity of prohibition. Drugs Alcohol Today 2010;10(1):14–21.Google Scholar
Measham, F, Wood, DM, Dargan, PI, Moore, K. The rise in legal highs: prevalence and patterns in the use of illegal drugs and first- and second-generation ‘legal highs’ in South London gay dance clubs. J Subst Use 2011;16(4):263–272.Google Scholar
Brunt, TM, Poortman, A, Niesink, RJ, van den Brink W. Instability of the ecstasy market and a new kid on the block: mephedrone. J Psychopharmacol 2011;25(11):1543–1547. https://doi.org/10.1177/0269881110378370Google Scholar
Measham, F, Moore, K, Østergaard, J. Mephedrone, ‘Bubble’ and unidentified white powders: the contested identities of synthetic ‘legal highs’. Drugs Alcohol Today 2011;11(3):137–146.Google Scholar
World Drug Report 2019 (United Nations publication, Sales No. E.19.XI.9).Google Scholar
Home Office. Drugs Misuse: Findings from the 2018/19 Crime Survey for England and Wales Statistical Bulletin. Published 19 September 2019.Google Scholar
Winstock, A, Mitcheson, L, Marsden, J. Mephedrone: still available and twice the price. Lancet 2010;376:1537.Google Scholar
Dybdal-Hargreaves, NF, Holder, ND, Ottoson, PE, Sweeney, MD, Williams, T. Mephedrone: public health risk, mechanisms of action, and behavioural effects. Eur J Pharmacol 2013;714(1–3):32–40. https://doi.org/10.1016/j.ejphar.2013.05.024Google Scholar
Wood, DM, Greene, SL, Dargan, PI. Emergency department presentations in determining the effectiveness of drug control in the United Kingdom: mephedrone (4-methylmethcathinone) control appears to be effective using this model. Emerg Med J 2013;30:70–71.Google Scholar
Sande M. Characteristics of the use of 3-MMC and other new psychoactive drugs in Slovenia. Int J Drug Policy 2016;27:65–73.Google Scholar
Tarján, A, Dudás, M, Gyarmathy, VA, Rusvai, E, Tresó, B, Csohán, Á. Emerging risks due to new injecting patterns in Hungary during austerity times. Subst Use Misuse 2015;50(7):848–858.Google Scholar
Belackova V, , Vacek J, , Janikova B, et al. ‘Just another drug’ for marginalized users: the risks of using synthetic cathinones among NSP clients in the Czech Republic. J Subst Use 2017;22(6):567–573. doi.org/10.1080/14659891.2016.1271034Google Scholar
Home Office. Drug Misuse: Findings from the 2013/14 Crime Survey for England and Wales. London, Home Office. Published July 2014.Google Scholar
European Monitoring Centre for Drugs and Drug Addiction (EMCDDA). European Drugs Report 2014. Trends and Developments. Luxembourg, Publications Office of the European Union, 2014.Google Scholar
Colfax, G, Santos, GM, Chu, P, et al. Amphetamine-group substances and HIV. Lancet 2010;376:458–474.Google Scholar
World Drug Report 2019 (United Nations publication, Sales No. E.19.XI.9).Google Scholar
Péterfi, A, Tarján, A, Horváth, GC, Csesztregi, T, Nyírády, A. Changes in patterns of injecting drug use in Hungary: a shift to synthetic cathinones. Drug Test Anal 2014;6(7–8):825–831.https://doi.org/10.1002/dta.1625Google Scholar
Kapitány-Fövény M, , Rácz J., Synthetic cannabinoid and synthetic cathinone use in Hungary: a literature review. Dev Health Sci 2018;1(3):63–69. https://doi.org/10.1556/2066.2.2018.18Google Scholar
Kapitány-Fövény M, , Rácz J., Synthetic cannabinoid and synthetic cathinone use in Hungary: a literature review. Dev Health Sci 2018;1(3):63–69. https://doi.org/10.1556/2066.2.2018.18Google Scholar
Péterfi A, Tarján A, Csaba Horváth G, Csesztregi T, Nyírády A. Changes in patterns of injecting drug use in Hungary: a shift to synthetic cathinones. Drug Test Anal 2014 (online). https://doi.org/10.1002/dta.1625Google Scholar
World Drug Report 2020 (United Nations publication, Sales No. E.20.XI.6).Google Scholar
European Monitoring Centre for Drugs and Drug Addiction (EMCDDA). European Drug Report 2018: Trends and Developments. Luxembourg, Publications Office of the European Union, 2018.Google Scholar
McNamara, S, Stokes, S, Coleman, N. Head shop compound abuse amongst attendees of the Drug Treatment Centre Board. Int Med J 2010;103(5):134–137.Google Scholar
Van Hout, MC, Bingham, T. ‘A costly turn on’: patterns of use and perceived consequences of mephedrone-based head shop products amongst Irish injectors. Int J Drug Policy 23;2012:188–197.Google Scholar
Bourne A, Reid D, Hickson F, Torres Rueda S, Weatherburn P. The chemsex study: drug use in sexual settings among gay and bisexual men in Lambeth, Southwark and Lewisham. London, Sigma Research, London School of Hygiene & Tropical Medicine. Available at: www.sigmaresearch.org.uk/chemsex [last accessed 17 March 2022].Google Scholar
Public Health England. Substance Misuse Services for Men Who Have Sex with Men Involved in Chemsex. London, Public Health England, 2015.Google Scholar
Semple, SJ, Patterson, TL, Grant, I. A comparison of injection and non-injection methamphetamine using HIV positive men who have sex with men. Drug Alcohol Depend 2004;76:203–212.Google Scholar
Van Hout, MC, Brennan, R. ‘Bump and grind’: an exploratory study of mephedrone users’ perceptions of sexuality and sexual risk. Drugs Alcohol Today 2012;11(2):93–103.Google Scholar
Frohmader, KS, Pitchers, KL, Balfour, M, Coolen, LM. Mixing pleasures: review of the effects of drugs on sex behavior in humans and animal models. Hormones Behav 2010;58:149–162.Google Scholar
Raj, A, Saitz, R, Cheng, DM, Winter, M, Samet, JH. Associations between alcohol, heroin, and cocaine use and high-risk sexual behaviors among detoxification patients. Am J Drug Alcohol Abuse 2007;33:169–178.Google Scholar
Mitcheson, L, McCambridge, J, Byrne, A, Hunt, N, Winstock, A. Sexual health risk among dance drug users: cross-sectional comparisons with nationally representative data. J Drug Policy 2008;19:304–310.Google Scholar
Sande M, , Paš M, , Nahtigal K, , Šabić S. Patterns of NPS use and risk reduction in Slovenia. Subst Use Misuse 2018;53(9):1424–1432. doi.org/10.1080/10826084.2017.1411366Google Scholar
Ciudad‐Roberts, A, Duart‐Castells, L, Camarasa, J, Pubill, D, Escubedo, E. The combination of ethanol with mephedrone increases the signs of neurotoxicity and impairs neurogenesis and learning in adolescent CD‐1 mice. Toxicol Appl Pharmacol 2016;293:10–20. https://doi.org/10.1016/j.taap.2015.12.019.Google Scholar
Carhart-Harris, RL, King, LA, Nutt, DJ. A web-based survey on mephedrone. Drug Alcohol Depend 2011;118:19–22.Google Scholar
Wood, DM, Greene, SL, Dargan, PI. Clinical pattern of toxicity associated with the novel synthetic cathinone mephedrone. Emergency Med J 2010;28:280–282. https://doi.org/0:10.1136/emj.2010.092288Google Scholar
Winstock, A, Mitcheson, L, Ramsey, J, Davies, S, Puchnarewicz, M, Marsden, J. Mephedrone: use, subjective effects and health risks. Addiction 2011;106(11):1991–1996.Google Scholar
Centre for Disease Control and Prevention. Emergency department visits after use of a drug sold as ‘bath salts’. Morb Mort Wkly Rep 2011;60(19):624–627.Google Scholar
Spiller, HA, Ryan, ML, Weston, RG, Jansen, J. Clinical experience with and analytical confirmation of ‘bath salts’ and ‘legal highs’ (synthetic cathinones) in the United States. Clin Toxicol 2011;49:499–505. https://doi.org/10.3109/15563650.2011.590812Google Scholar
Winstock, A, Mitcheson, L, Ramsey, J, et al. Mephedrone: use, subjective effects and health risks. Addiction 2011;106:1991–1996. https://doi.org/10.1111/j.1360-0443.2011.03502.xGoogle Scholar
Assi, S, Gulyamova, N, Ibrahim, K, et al. Profile, effects, and toxicity of novel psychoactive substances: a systematic review of quantitative studies. Hum Psychopharmacol Clin Exp 2017;32:e2607. https://doi.org/10.1002/hup.2607Google Scholar
Assi, S, Gulyamova, N, Kneller, P, Osselton, D. The effects and toxicity of cathinones from the users’ perspectives: a qualitative study. Hum Psychopharmacol Clin Exp 2017;32:e2610. https://doi.org/10.1002/hup.2610Google Scholar
Zuba, D, Byrska, B. Prevalence and co-existence of active components of ‘legal highs’. Drug Test Anal 2013;5(6):420–429. https://doi.org/10.1002/dta.1365Google Scholar
Schifano, F, Albanese, A, Fergus, S, et al. Psychonaut Web Mapping; ReDNet Research Groups. Mephedrone (4-methylmethcathinone; ‘meow meow’): chemical, pharmacological and clinical issues. Psychopharmacology 2011;214(3):593–602. https://doi.org/10.1007/s00213-010-2070-xCrossRefGoogle Scholar
Marinetti, LJ, Antonides, HM. Analysis of synthetic cathinones commonly found in bath salts in human performance and post-mortem toxicology: method development, drug distribution and interpretation of results. J Anal Toxicol 2013;37(3):135–146. https://doi.org/10.1093/jat/bks136Google Scholar
McElrath, K, O’Neill, C. Experiences with mephedrone pre- and post-legislative control: perceptions of safety and sources of supply. Int J Drug Policy 2011;22:120–127.Google Scholar
Deluca, P, Schifano, F, Davey, Z, Corazza, O, Di Furia, L. The Psychonaut Web Mapping Research Group. Mephedrone Report. London, Institute of Psychiatry, King’s College London, 2009. Available at: www.psychonautproject.eu [last accessed 17 March 2022].Google Scholar
Karila, L, Reynaud, M. GHB and synthetic cathinones: clinical effects and potential consequences. Drug Test Anal 2011;3:552–559.Google Scholar
Sande M, , Paš M, , Nahtigal K, , Šabić, S. Patterns of NPS use and risk reduction in Slovenia. Subst Use Misuse 2018;53(9):1424–1432. doi.org/10.1080/10826084.2017.1411366Google Scholar
Dargan PI, Wood DM. Annex 1 to the risk assessment report Technical Report on Mephedrone. EMCDDA contract CT.10.EPI.057. Guy’s and St Thomas’ NHS Foundation Trust, London, 2010. Available at: www.emcdda.europa.eu [last accessed 17 March 2022].Google Scholar
Wood, DM, Davies, S, Greene, SL, et al. Case series of individuals with analytically confirmed acute mephedrone toxicity. Clin Toxicol 2010;48:924–927.Google Scholar
Martínez-Clemente, J, López-Arnau, R, Carbó, M, Pubill, D, Camarasa, J, Escubedo, E. Mephedrone pharmacokinetics after intravenous and oral administration in rats: relation to pharmacodynamics. Psychopharmacology 2013;229(2):295–306.Google Scholar
Yanagihara, Y, Kariya, S, Ohtani, M, et al. Involvement of CYP2B6 in n-demethylation of ketamine in human liver microsomes. Drug Metab Dispos 2001;29:887–890.Google Scholar
Hijazi, Y, Boulieu, R. Contribution of CYP3A4, CYP2B6, and CYP2C9 isoforms to N-demethylation of ketamine in human liver microsomes. Drug Metab Dispos 2002,30:853–858.Google Scholar
Office for National Statistics. Drug Misuse Declared: Findings from the 2011/12 Crime Survey for England and Wales (2nd ed.). London, Home Office, July 2012.Google Scholar
Archer, JRH, Dargan, PI, Hudson, S, Wood, DM. Analysis of anonymous pooled urine from portable urinals in central London confirms the significant use of novel psychoactive substances. Q J Med 2013;106:147–152.Google Scholar
National Poisons Information Service (NIPS). Annual Report 2010/11. Health Protection Agency, 2011.Google Scholar
National Poisons Information Service (NIPS). Annual Report 2011/12. Health Protection Agency, 2012.Google Scholar
Wood, DM, Measham, F, Dargan, PI. ‘Our favourite drug’: prevalence of use and preference for mephedrone in the London night-time economy 1 year after control. J Subst Use 2012;17(2):91–97.Google Scholar
Welsh Government. Working Together to Reduce Harm. Substance Misuse Annual Report 2013.Google Scholar
Moore, K, Dargan, PI, Wood, DM, Measham, F. Do novel psychoactive substances displace established club drugs, supplement them or act as drugs of initiation? The relationship between mephedrone, ecstasy and cocaine. Eur Addict Res 2013;19(5):276–282.Google Scholar
DrugScope. DrugScope street drug trends survey highlights growing problems with mephedrone. Published 22 November 2012.Google Scholar
Kirby, T, Thornber-Dunwell, M. High-risk drug practices tighten grip on London gay scene. Lancet 2013;381(9861):101–102. https://doi.org/10.1016/S0140-6736(13)60032-XGoogle Scholar
James, D, Adams, RD, Spears, R, et al. National Poisons Information Service. Clinical characteristics of mephedrone toxicity reported to the UK National Poisons Information Service. Emerg Med J 2011;28(8):686–689. https://doi.org/10.1136/emj.2010.096636Google Scholar
Winstock, AR, Mitcheson, LR, Deluca, P, et al. Mephedrone, new kid for the chop? Addiction 2011;106(1):154–161.Google Scholar
Wood, DM, Davies, S, Puchnarewicz, M, et al. Recreational use of mephedrone (4-methylmethcathinone, 4-MMC) with associated sympathomimetic toxicity. J Med Toxicol 2010;6(3):327–330.Google Scholar
Newcombe, R. Mephedrone: Use of Mephedrone (M-Cat, Meow) in Middlesbrough. Lifeline, Manchester, 2009.Google Scholar
Winstock, AR, Marsden, J, Mitcheson, L. What should be done about mephedrone? Br Med J 2010;340:c1605.Google Scholar
Dargan, PI, Sedefov, R, Gallegos, A, Wood, DM. The pharmacology and toxicology of the synthetic cathinonemephedrone (4-methylmethcathinone). Drug Test Anal 2011;3(7–8):454–463. https://doi.org/10.1002/dta.312Google Scholar
Rosenbaum, CD, Carreiro, SP, Babu, KM. Here today, gone tomorrow … and back again? A review of herbal marijuana alternatives (K2, Spice), synthetic cathinones (bath salts), kratom, Salvia divinorum, methoxetamine, and piperazines. J Med Toxicol 2012;8(1):15–32. https://doi.org/10.1007/s13181-011-0202-2Google Scholar
Freeman, TP, Morgan, CJ, Vaughn-Jones, J, Hussain, N, Karimi, K, Curran, HV. Cognitive and subjective effects of mephedrone and factors influencing use of a ‘new legal high’. Addiction 2012;107(4):792–800. https://doi.org/10.1111/j.1360-0443.2011.03719.xGoogle Scholar
Motbey, CP, Clemens, KJ, Apetz, N, et al. High levels of intravenous mephedrone (4-methylmethcathinone) self-administration in rats: neural consequences and comparison with methamphetamine. J Psychopharmacol 2013;27(9):823–836. https://doi.org/10.1177/0269881113490325Google Scholar
Annex 2. Technical Report on 1-(1,3-benzodioxol-5-yl)-2-(pyrrolidin-1-yl)pentan-1-one (3,4-methylenedioxypyrovalerone, MDPV). Prepared by Ms Alison M Dines, Dr David M Wood and Dr Paul I Dargan.Google Scholar
European Monitoring Centre for Drugs and Drug Addiction and Europol. Joint Report on a New Psychoactive Substance: MDPV (3,4-methylenedioxypyrovalerone). Available at: www.emcdda.europa.eu/system/files/publications/819/TDAS14001ENN_466653.pdf[last accessed 17 March 2022].Google Scholar
Annex 2. Technical Report on 1-(1,3-benzodioxol-5-yl)-2-(pyrrolidin-1-yl)pentan-1-one (3,4-methylenedioxypyrovalerone, MDPV). Prepared by Ms Alison M Dines, Dr David M Wood and Dr Paul I Dargan.Google Scholar
Coppola M, Mondola R. Synthetic cathinones: chemistry, pharmacology and toxicology of a new class of designer drugs of abuse marketed as ‘bath salts’ or ‘plant food’. Toxicol Lett 2012;211(2):144–149. https://doi.org/10.1016/j.toxlet.2012.03.009Google Scholar
European Monitoring Centre for Drugs and Drug Addiction (EMCDDA). The state of the drugs problem in Europe – Annual report 2012. Luxembourg: Publications Office of the European Union, 2012. https://doi.org/10.2810/64775. Available at: www.emcdda.europa.eu/attachements.cfm/att_190854_EN_TDAC12001ENC_.pdf [last accessed 17 March 2022].Google Scholar
Ashrafioun L, Bonadio FA, Baik KD, et al. Patterns of use, acute subjective experiences, and motivations for using synthetic cathinones (‘bath salts’) in recreational users. J Psychoactive Drugs 2016;48(5):336–343. https://doi.org/10.1080/02791072.2016.1229875Google Scholar
Ashrafioun, L, Bonadio, FA, Baik, KD, et al. Patterns of use, acute subjective experiences, and motivations for using synthetic cathinones (‘bath salts’) in recreational users. J Psychoactive Drugs 2016;48(5):336–343. https://doi.org/10.1080/02791072.2016.1229875Google Scholar
Ashrafioun, L, Bonadio, FA, Baik, KD, et al. Patterns of use, acute subjective experiences, and motivations for using synthetic cathinones (‘bath salts’) in recreational users. J Psychoactive Drugs 2016;48(5):336–343. https://doi.org/10.1080/02791072.2016.1229875Google Scholar
Wood, DM, Dargan, PI. Mephedrone (4-methylmethcathinone): what is new in our understanding of its use and toxicity. Prog Neuropsychopharmacol Biol Psychiatry 2012;39(2):227–233. https://doi.org/10.1016/j.pnpbp.2012.04.020Google Scholar
Weinstein AM, Rosca P, Fattore L. London ED. Synthetic cathinone and cannabinoid designer drugs pose a major risk for public health. Front Psychiatry 2017;8:156.Google Scholar
Van Hout, MC, Brennan, R. ‘Bump and grind’: an exploratory study of mephedrone users’ perceptions of sexuality and sexual risk. Drugs Alcohol Today 2012;11(2):93–103.Google Scholar
Semple, SJ, Patterson, TL, Grant, I. Motivations associated with methamphetamine use among HIV men who have sex with men. J Subst Abuse Treat 2002;22:149–156.Google Scholar
Frohmader, KS, Pitchers, KL, Balfour, M, Coolen, LM. Mixing pleasures: review of the effects of drugs on sex behavior in humans and animal models. Horm Behav 2010;58:149–162.Google Scholar
Raj, A, Saitz, R, Cheng, DM, Winter, M, Samet, JH. Associations between alcohol, heroin, and cocaine use and high-risk sexual behaviors among detoxification patients. Am J Drug Alcohol Abuse 2007;33:169–178.Google Scholar
Mitcheson, L, McCambridge, J, Byrne, A, Hunt, N, Winstock, A. Sexual health risk among dance drug users: cross-sectional comparisons with nationally representative data. J Drug Policy 2008;19:304–310.Google Scholar
Rhodes, T, Quirk, A. Drug users’ sexual relationships and the social organization of risk: the sexual relationship as a site of risk management. Soc Sci Med 1998;46(2):157–169.Google Scholar
Winstock A. The Mixmag Drugs Survey. Mixmag, April 2012. Available at: https://issuu.com/mixmagfashion/docs/drugs_survey_2012_2 [last accessed 17 March 2022].Google Scholar
Winstock A. The Mixmag Drugs Survey. Mixmag, April 2012. Available at: https://issuu.com/mixmagfashion/docs/drugs_survey_2012_2 [last accessed 17 March 2022].Google Scholar
Dargan, PI, Albert, S, Wood, DM. Mephedrone use and associated adverse effects in school and college/university students before the UK legislation change. QJM 2010;103(11):875–879.Google Scholar
Schifano, F, Corkery, J, Naidoo, V, Oyefeso, A, Ghodse, AH. Comparison between amphetamine/methylamphetamine and ecstasy (MDMA, MDEA, MDA, 4-MTA) mortality data in the UK (1997–2007). Neuropsychobiology 2010;61:122–130.Google Scholar
Dickson, AJ, Vorce, SP, Levine, B, Past, MR. Multiple-drug toxicity caused by the coadministration of 4-methylmethcathinone (mephedrone) and heroin. J Analytic Toxicol 2010;34:162–168.Google Scholar
Corkery, JM, Schifano, F, Ghodse, AH. Mephedrone-related fatalities in the United Kingdom: contextual, clinical and practical issues. InTech-Open Access Publisher, 14 March 2012.Google Scholar
Colon-Perez LM, Tran K, Thompson K, et al. The psychoactive designer drug and bath salt constituent MDPV causes widespread disruption of brain functional connectivity. Neuropsychopharmacology 2016;41:2352–2365.Google Scholar
Fujita Y, , Mita T, , Usui K, et al. Toxicokinetics of the synthetic cathinone α-Pyrrolidinohexanophenone. J Anal Toxicol 2018;42:e1–e5. https://doi.org/10.1093/jat/bkx080Google Scholar
Antonowicz, JL, Metzger, AK, Ramanujam, SL. Paranoid psychosis induced by consumption of methylenedioxypyrovalerone: two cases. Gen Hosp Psych 2011;33(640):e5.Google Scholar
Boulanger-Gobeil, C, St-Onge, M, Laliberte, M, Auger, PL. Seizures and hyponatremia related to ethcathinone and methylone poisoning. J Med Toxicol 2012;8(1):59–61.Google Scholar
European Monitoring Centre for Drugs and Drug Addiction. Drug profiles. Synthetic cathinones, 2012. Availableat:www.emcdda.europa.eu/publications/drug-profiles/synthetic-cathinones[last accessed 17 March 2022].Google Scholar
Derungs, A, Schietzel, S, Meyer, MR, Maurer, HH, Kr€ahenb€uhl, S, Liechti, ME. Sympathomimetic toxicity in a case of analytically confirmed recreational use of naphyrone (naphthylpyrovalerone). Clin Toxicol 2011;49(7):691–693.Google Scholar
Winder, GS, Stern, N, Are, Hosanagar A. ‘bath salts’ the next generation of stimulant abuse? J Subst Abuse Treat 2013;44(1):42–45.Google Scholar
Spiller, HA, Ryan, ML, Weston, RG, Jansen, J. Clinical experience with and analytical confirmation of ‘bath salts’ and ‘legal highs’ (synthetic cathinones) in the United States. Clin Toxicol 2011;49(6):499–505.Google Scholar
Centers for Disease Control and Prevention (CDC). Emergency department visits after use of a drug sold as bath salts – Michigan, November 13, 2010 to March 31, 2011. MMWR Morb Mortal Wkly Rep 2011;60(19):624–627. Available at: www.cdc.gov/mmwr/preview/mmwrhtml/mm6019a6.htm [last accessed 17 March 2022].Google Scholar
Zawilska, JB, Słomiak, K, Wasiak, M, et al. Beta-cathinone derivatives – a new generation of dangerous psychostimulant ‘designer drugs’. Przegl Lek 2013;70(6):386–391.Google Scholar
Kelly, JP. Cathinone derivatives: a review of their chemistry, pharmacology and toxicology. Drug Test Anal 2011;3(7–8):43953.Google Scholar
Thornton, SL, Gerona, RR, Tomaszewski, CA. Psychosis from a bath salt product containing flephedrone and MDPV with serum, urine, and product quantification. J Med Toxicol 2012;8(3):310–313.Google Scholar
Wood, DM, Davies, S, Greene, SL, et al. Case series of individuals with analytically confirmed acute mephedrone toxicity. Clin Toxicol 2010;48:924–927.Google Scholar
Wood, DM, Davies, S, Puchnarewicz, M, et al. Recreational use of mephedrone (4-methylmethcathinone, 4-MMC) with associated sympathomimetic toxicity. J Med Toxicol 2010;6(3):327–330.Google Scholar
Wood, DM, Greene, SL, Dargan, PI. Clinical pattern of toxicity associated with the novel synthetic cathinone mephedrone. Emergency Med J 2010;28:280–282. https://doi.org/0:10.1136/emj.2010.092288Google Scholar
Nicholson PJ, Quinn MJ, Dodd JD. Headshop heartache: acute mephedrone meow myocarditis. Heart 2010;96:2051.Google Scholar
Sammler, EM, Foley, PL, Lauder, GD, Wilson, SJ, Goudie, AR, O’Riordan, JI. A harmless high? Lancet 2010;376:742.Google Scholar
Benzie F, Hekman K, Cameron L, et al. Emergency department visits after use of a drug sold as ‘bath salts’ – Michigan, November 13, 2010 to March 31, 2011. Morb Mort Wkly Rep 2011;60(19):624–627.Google Scholar
Hadlock, GC, Webb, KM, McFadden, LM, et al. 4-Methylmethcathinone (mephedrone): neuropharmacological effects of a designer stimulant of abuse. J Pharmacol Exp Ther 2011;339(2):530–536. https://doi.org/10.1124/jpet.111.184119Google Scholar
Winstock AR, Mitcheson LR, Deluca, P, et al. Mephedrone, new kid for the chop? Addiction 2011;106(1):154–161.Google Scholar
Dargan, PI, Sedefov, R, Gallegos, A, Wood, DM. The pharmacology and toxicology of the synthetic cathinonemephedrone (4-methylmethcathinone). Drug Test Anal 2011;3(7–8):454–463. https://doi.org/10.1002/dta.312Google Scholar
Wood, DM, Dargan, PI. Understanding how data triangulation identifies acute toxicity of novel psychoactive drugs. J Med Toxicol 2012;8:300–303. https://doi.org/10.1007/s13181-012-0241-3Google Scholar
Dybdal-Hargreaves, N, Holder, N, Ottoson, P, Sweeney, M, Williams, T. Mephedrone: public health risk, mechanisms of action and behaviorial effects. Eur J Pharmacol 2013;714:32–40.Google Scholar
Zawilska, J, Wojcieszak, J. Designer cathinone—an emerging class of novel recreational drugs. Forensic Sci Int 2013;231:42–53.Google Scholar
Fleckenstein, AE, Volz, TJ, Riddle, EL, Gibb, JW, Hanson, GR. New insights into the mechanism of action of amphetamines. Annu Rev Pharmacol Toxicol 2007;47:681–698.Google Scholar
Coppola, M, Mondola, R. Synthetic cathinones: chemistry, pharmacology and toxicology of a new class of designer drugs of abuse marketed as ‘bath salts’ or ‘plant food’. Toxicol Lett 2012;211(2):144–149. https://doi.org/10.1016/j.toxlet.2012.03.009. 8Google Scholar
Carroll, FI, Lewin, AH, Mascarella, SW, Seltzman, HH, Reddy, PA. Designer drugs: a medicinal chemistry perspective. Ann NY Acad Sci 2012;1248:18–38.Google Scholar
Iversen, L, White, M, Treble, R. Designer psychostimulants: pharmacology and differences. Neuropharmacology 2014;87:59–65. https://doi.org/10.1016/j.neuropharm.2014.01.015Google Scholar
Luethi D, Kolaczynska KE, Docci L, Krahenbuhl S, Hoener MC, Liechti ME. Pharmacological profile of mephedrone analogs and related new psychoactive substances. Neuropharmacology 2017;26:4–12.Google Scholar
Weinstein AM, Rosca P, Fattore L, London ED. Synthetic cathinone and cannabinoid designer drugs pose a major risk for public health. Front Psychiatry 2017;8:156.Google Scholar
Nicholson, PJ, Quinn, MJ, Dodd, JD. Headshop heartache: acute mephedrone meow myocarditis. Heart 2010;96:2051.Google Scholar
Sammler, EM, Foley, PL, Lauder, GD, Wilson, SJ, Goudie, AR, O’Riordan, JI. A harmless high? Lancet 2010;376:742.Google Scholar
Benzie, F, Hekman, K, Cameron, L, et al. Emergency department visits after use of a drug sold as ‘bath salts’ – Michigan, November 13, 2010–March 31, 2011.
Morb Mort Wkly Rep 2011;60(19):624–627.Google Scholar
Wood, DM, Dargan, PI. Understanding how data triangulation identifies acute toxicity of novel psychoactive drugs. J Med Toxicol 2012;8:300–303. https://doi.org/10.1007/s13181-012-0241-3Google Scholar
Fujita Y, , Mita T, , Usui, K, et al. Toxicokinetics of the synthetic cathinone α-pyrrolidinohexanophenone. J Anal Toxicol 2018;42:e1–e5. https://doi.org/10.1093/jat/bkx080Google Scholar
Prosser, JM, Nelson, LS. The toxicology of bath salts: a review of synthetic cathinones. J Med Toxicol 2012;8:33–42.Google Scholar
Chhabra, JS, Nandalan, S, Saad, R. Mephedrone poisoning – a case of severe refractory left ventricular failure. Poster Presentation 33. In: The State of the Art Meeting, London, 13–14 December 2010, pp. 74–75.Google Scholar
Garrett, G, Sweeney, M. The serotonin syndrome as a result of mephedrone toxicity. BMJ Case Rep 2010;2010:bcr0420102925. https://doi.org/10.1136/bcr.04.2010.2925Google Scholar
Mugele, J, Nañagas, KA, Tormoehlen, LM. Serotonin syndrome associated with MDPV use: a case report. Ann Emerg Med 2012;60(1):100–102. https://doi.org/10.1016/j.annemergmed.2011.11.033Google Scholar
German, CL, Fleckenstein, AE, Hanson, GR. Bath salts and synthetic cathinones: an emerging designer drug phenomenon. Life Sci 2014;97:2–8.Google Scholar
Angoa-Perez, M, Kane, MJ, Francescutti, DM, et al. Mephedrone, an abused psychoactive component of ‘bath salts’ and methamphetamine congener, does not cause neurotoxicity to dopamine nerve endings of the striatum. J Neurochem 2012;120(6):1097–1107.Google Scholar
Fass, JA, Fass, AD, Garcia, AS. Synthetic cathinones (bath salts): legal status and patterns of abuse. Ann Pharmacother 2012;46(3):436–441.Google Scholar
Omer, TA, Doherty, C. Posterior reversible encephalopathy syndrome (PRES) complicating the ‘legal high’ mephedrone. BMJ Case Rep 2011;2011:bcr0220113904. https://doi.org/10.1136/bcr.02.2011.3904Google Scholar
Maan, ZN, D’Souza, AR. Spontaneous subcutaneous emphysema associated with mephedrone usage. Ann R Coll Surg Engl 2012;94(1):e38–40. https://doi.org/10.1308/003588412X13171221499108Google Scholar
Ahmed, N, Hoy, BP, McInerney, J. Methaemoglobinaemia due to mephedrone (‘snow’). BMJ Case Rep 2010;2010:bcr0420102879. https://doi.org/10.1136/bcr.04.2010.2879Google Scholar
Ramirez Berlioz A, Gardner M. MON-146 prolonged hypoglycemia in the setting of synthetic cathinone abuse. J Endocr Soc 2019;3(Suppl. 1):146. https://doi.org/10.1210/js.2019-MON-146Google Scholar
Wong, ML, Holt, RI. The potential dangers of mephedrone in people with diabetes: a case report. Drug Test Anal 2011;3(7–8):464–465. https://doi.org/10.1002/dta.316Google Scholar
Leyrer-Jackson JM, Nagy EK, Olive MF. Cognitive deficits and neurotoxicity induced by synthetic cathinones: is there a role for neuroinflammation? Psychopharmacology 2019;236(3);1079–1095. 10.1007/s00213-018-5067-5doi.org/Google Scholar
Wood, DM, Davies, S, Greene, SL, et al. Case series of individuals with analytically confirmed acute mephedrone toxicity. Clin Toxicol 2010;48:924–927.Google Scholar
Wood, DM, Davies, S, Puchnarewicz, M, et al. Recreational use of mephedrone (4-methylmethcathinone, 4-MMC) with associated sympathomimetic toxicity. J Med Toxicol 2010;6(3):327–330.Google Scholar
Wood, DM, Greene, SL, Dargan, PI. Clinical pattern of toxicity associated with the novel synthetic cathinone mephedrone. Emergency Med J 2010;28:280–282. https://doi.org/0:10.1136/emj.2010.092288Google Scholar
Nicholson PJ, Quinn MJ, Dodd JD. Headshop heartache: acute mephedrone meow myocarditis. Heart 2010;96:2051.Google Scholar
Sammler, EM, Foley, PL, Lauder, GD, Wilson, SJ, Goudie, AR, O’Riordan, JI. A harmless high? Lancet 2010;376:742.Google Scholar
Benzie, F, Hekman, K, Cameron, L, et al. Emergency department visits after use of a drug sold as ‘bath salts’ – Michigan, November 13, 2010–March 31, 2011. Morb Mort Wkly Rep 2011;60(19):624–627.Google Scholar
Hadlock, GC, Webb, KM, McFadden, LM, et al. 4-Methylmethcathinone (mephedrone): neuropharmacological effects of a designer stimulant of abuse. J Pharmacol Exp Ther 2011;339(2):530–536. https://doi.org10.1124/jpet.111.184119Google Scholar
Winstock, A, Mitcheson, L, Ramsey, J, Davies, S, Puchnarewicz, M, Marsden, J. Mephedrone: use, subjective effects and health risks. Addiction 2011;106:1991–1996.Google Scholar
Papaseit E, Olesti E, de la Torre R, Torrens M, Farre M. Mephedrone concentrations in cases of clinical intoxication. Curr Pharm Des 2017;4:5511–5522.Google Scholar
Wood, DM, Davies, S, Puchnarewicz, M, et al. Recreational use of mephedrone (4-methylmethcathinone, 4-MMC) with associated sympathomimetic toxicity. J Med Toxicol 2010;6(3):327–330.Google Scholar
Winestock, AR, Mitcheson, LR, Deluca, P, et al. Mephedrone, new kid for the chop? Addiction 2011;106(1):154–161.Google Scholar
Dargan, PI, Sedefov, R, Gallegos, A, Wood, DM. The pharmacology and toxicology of the synthetic cathinone mephedrone (4-methylmethcathinone). Drug Test Anal 2011;3(7–8):454–463. https://doi.org/10.1002/dta.312Google Scholar
Benzie F, Hekman K, Cameron L, et al. Emergency department visits after use of a drug sold as ‘bath salts’ – Michigan, November 13, 2010–March 31, 2011. Morb Mort Wkly Rep 2011;60(19):624–627.Google Scholar
Wood, DM, Dargan, PI. Understanding how data triangulation identifies acute toxicity of novel psychoactive drugs. J Med Toxicol 2012;8:300–303. https://doi.org/10.1007/s13181-012-0241-3Google Scholar
Dybdal-Hargreaves, N, Holder, N, Ottoson, P, Sweeney, M, Williams, T. Mephedrone: public health risk, mechanisms of action and behaviorial effects. Eur J Pharmacol 2013; 714:32–40.Google Scholar
Zawilska, J, Wojcieszak, J. Designer cathinone: an emerging class of novel recreational drugs. Forensic Sci Int 2013; 231:42–53.Google Scholar
Wood, D, Davies, S, Puchnarewicz, M, et al. Recreational use of mephedrone (4-methylmethcathinone, 4-MMC) with associated sympathomimetic toxicity. J Med Toxicol 2010; 6:327–330.Google Scholar
Kolli, V, Sharma, A, Amani, M, Bestha, D, Chaturvedi, R. ‘Meow meow’ (mephedrone) and catatonia. Innov Clin Neurosci 2013;10(2):11–12.Google Scholar
Prosser, JM, Nelson, LS. The toxicology of bath salts: a review of synthetic cathinones. J Med Toxicol 2012;8(1):33–42.Google Scholar
Szily, E., Bitter, I. Designer drugs in psychiatric practise – a review of the literature and recent situation in Hungary. Neuropsychopharmacol Hung 2013;5(4): 223–231.Google Scholar
Segrec N, , Kastelic A, , Pregelj P. Pentedrone-induced acute psychosis in a patient with opioid addiction: a case report. Case Rep Heroin Addict Relat Clin Probl 2016;18(3):53–56.Google Scholar
Weinstein AM, Rosca P, Fattore L. London ED. Synthetic cathinone and cannabinoid designer drugs pose a major risk for public health. Front Psychiatry 2017;8:156.Google Scholar
Prosser, JM, Nelson, LS. The toxicology of bath salts: a review of synthetic cathinones. JMed Toxicol 2012;8(1):33–42.Google Scholar
Szily, E, Bitter, I. Designer drugs in psychiatric practise – a review of the literature and recent situation in Hungary. Neuropsychopharmacol 2013;5(4):223–231.Google Scholar
Segrec, N, Kastelic, A, Pregelj, P. Pentedrone-induced acute psychosis in a patient with opioid addiction: a case report. Heroin Addict Relat Clin Probl 2016;18(3):53–56.Google Scholar
Antonowicz, JL, Metzger, AK, Ramanujam, SL. Paranoid psychosis induced by consumption of methylenedioxypyrovalerone: two cases. Gen Hosp Psychiatry 2011;33(6):640.Google Scholar
Farkas, K, Sirály, E, Szily, E, Csukly, G, Réthelyi, J. Clinical characteristics of 5 hospitalized 3,4-methylenedioxypyrovalerone (MDPV) users. Psychiatr Hung 2013;28(4):431–439.Google Scholar
Stiles BM, Fish AF, Cook CA, Silva V. Bath salt-induced psychosis: nursing assessment, diagnosis, treatment, and outcomes. Perspect Psychiatr Care 2015;52(1):68–78.Google Scholar
Thornton, SL, Gerona, RR, Tomaszewski, CA. Psychosis from a bath salt product containing flephedrone and MDPV with serum, urine, and product quantification. J Med Toxicol 2012;8(3):310–313.Google Scholar
Segrec N, , Kastelic A, , Pregelj P. Pentedrone-induced acute psychosis in a patient with opioid addiction: a case report. Case Rep Heroin Addict Relat Clin Probl 2016;18(3):53–56.Google Scholar
Tekulve, K, Alexander, A, Tormoehlen, L. Seizures associated with synthetic cathinone exposures in the pediatric population. Pediatr Neurol 2014;51(1):67–70. https://doi.org/10.1016/j.pediatrneurol.2014.03.003Google Scholar
European Monitoring Centre for Drugs and Drug Addiction. Annex 2. Technical Report on 1-(1,3-benzodioxol-5-yl)-2-(pyrrolidin-1-yl)pentan-1-one (3,4-methylenedioxypyrovalerone, MDPV). Prepared by Ms Alison M Dines, Dr David M Wood and Dr Paul I Dargan.Google Scholar
Baumann, MH, Partilla, JS. Lehner, KR, et al. Powerful cocaine-like actions of 3,4-methylenedioxypyrovalerone (MDPV), a principal constituent of psychoactive ‘bath salts’ products. Neuropsychopharmcology 2013;38:552–562.Google Scholar
European Monitoring Centre for Drugs and Drug Addiction. Annex 2. Technical Report on 1-(1,3-benzodioxol-5-yl)-2-(pyrrolidin-1-yl)pentan-1-one (3,4-methylenedioxypyrovalerone, MDPV). Prepared by Ms Alison M Dines, Dr David M Wood and Dr Paul I Dargan.Google Scholar
Beck O, , Franzen L, , Bäckberg M, , Signell, P, Helander, A. Intoxications involving MDPV in Sweden during 2010–2014: results from the STRIDA project. Clin Toxicol 2015;53(9):865–873. https://doi.org/10.3109/15563650.2015.1089576Google Scholar
Lindeman E, Hulten P, Strom S, Enlund M, Al-Saffar Y, Helander A. Increased abuse of the Internet drug MDPV in Vastmanland. Severe cases of poisoning have given health care major problems. Lakartidningen 2012;109:1954–1957.Google Scholar
Beck O, , Franzen L, , Bäckberg M, , Signell, P, Helander, A. Intoxications involving MDPV in Sweden during 2010–2014: results from the STRIDA project. Clin Toxicol 2015;53(9):865–873. https://doi.org/10.3109/15563650.2015.1089576Google Scholar
Coppola M, Mondola R. 3,4-Methylenedioxypyrovalerone (MDPV): chemistry, pharmacology and toxicology of a new designer drug of abuse marketed online. Toxicol Lett 2012;208:12–15.Google Scholar
Simonsen, KW, Edvardsen, HME, Thelander, G, et al. Fatal poisoning in drug addicts in the Nordic countries in 2012. Forensic Sci Int 2015;248:172–180.Google Scholar
European Monitoring Centre for Drugs and Drug Addiction. Risk assessments of MDPV. Available at: www.emcdda.europa.eu/attachements.cfm/att_228256_EN_TDAK14003ENN.pdf [last accessed 18 March 2022].Google Scholar
Karila L, Lafay G, Scocard A, Cottencin O, Benyamins A. MDPV and α-PVP use in humans: the twisted sisters. Neuropharmacology 2018;134(Part A):65–72.Google Scholar
Csák R, Demetrovics Z, Rácz J. Transition to injecting 3,4-methylene-dioxy-pyrovalerone (MDPV) among needle exchange program participants in Hungary. J Psychopharmacol 2013;27(6):559–563. doi.org/10.1177/0269881113480987Google Scholar
Antonowicz, JL, Metzger, AK, Ramanujam, SL. Paranoid psychosis induced by consumption of methylenedioxypyrovalerone: two cases. Gen Hosp Psych 2011;33(640):e5.Google Scholar
Boulanger-Gobeil, C, St-Onge, M, Laliberte, M, Auger, PL. Seizures and hyponatremia related to ethcathinone and methylone poisoning. J Med Toxicol 2012;8(1):59–61.Google Scholar
European Monitoring Centre for Drugs and Drug Addiction. Drug profiles. Synthetic cathinones, 2012. Available at: www.emcdda.europa.eu/publications/drug-profiles/synthetic-cathinones_en [last accessed 18 March 2022].Google Scholar
Derungs, A, Schietzel, S, Meyer, MR, Maurer, HH, Kr€ahenb€uhl, S, Liechti, ME. Sympathomimetic toxicity in a case of analytically confirmed recreational use of naphyrone (naphthylpyrovalerone). Clin Toxicol 2011;49(7):691–693.Google Scholar
Winder, GS, Stern, N, Are, Hosanagar A. ‘bath salts’ the next generation of stimulant abuse? J Subst Abuse Treat 2013;44(1):42–45.Google Scholar
Spiller, HA, Ryan, ML, Weston, RG, Jansen, J. Clinical experience with and analytical confirmation of ‘bath salts’ and ‘legal highs’ (synthetic cathinones) in the United States. Clin Toxicol 2011;49(6):499–505.Google Scholar
Centers for Disease Control and Prevention (CDC). Emergency department visits after use of a drug sold as bath salts – Michigan, November 13, 2010 to March 31, 2011. Morb Mort Wkly Rep 2011;60(19):624–627.Google Scholar
Zawilska, JB, Słomiak, K, Wasiak, M, et al. Beta-cathinone derivatives: a new generation of dangerous psychostimulant ‘designer drugs’. Przegl Lek 2013;70(6):386–391.Google Scholar
Kelly, JP. Cathinone derivatives: a review of their chemistry, pharmacology and toxicology. Drug Test Anal 2011;3(7–8):43953.Google Scholar
Thornton, SL, Gerona, RR, Tomaszewski, CA. Psychosis from a bath salt product containing flephedrone and MDPV with serum, urine, and product quantification. J Med Toxicol 2012;8(3):310–313.Google Scholar
Péterfi A, Tarján A, Csaba Horváth G, Csesztregib T, Nyírády A. Changes in patterns of injecting drug use in Hungary: a shift to synthetic cathinones. Drug Test Anal 2014;6(7–8):825–831.Google Scholar
Botescu A, Abagiu A, Mardarescu M, Ursan M. HIV/AIDS among injecting drug users in Romania – report of a recent outbreak and initial response policies. EMCDDA, Lisbon, 2012. Available at: www.emcdda.europa.eu/publications/ad-hoc/2012/romania-hiv-update [last accessed 18 March 2022].Google Scholar
European Monitoring Centre for Drugs and Drug Addiction. Report on the risk assessment of mephedrone in the framework of the Council Decision on new psychoactive substances. EMCDDA, Lisbon, 2011.Google Scholar
Van Hout MC, , Bingham T, . ‘A costly turn on’: patterns of use and perceived consequences of mephedrone-based head shop products amongst Irish injectors. Int J Drug Policy 2012;23:188.Google Scholar
European Monitoring Centre for Drugs and Drug Addiction. High-risk drug use and new psychoactive substances. EMCDDA Rapid Communication. Luxembourg, Publications Office of the European Union.Google Scholar
Schifano, F, Corkery, C, Ghodse, AH. Background: suspected and confirmed fatalities associated with mephedrone (4-methylmethcathinone, ‘meow meow’) in the United Kingdom. J Clin Psychopharmacol 2012;32(5):710–714. https://doi.org/10.1097/JCP.0b013e318266c70cGoogle Scholar
Pacifici, R, Zuccaro, P, Farre, M, et al. Cell-mediated immune response in MDMA users after repeated dose administration: studies in controlled versus noncontrolled settings. Ann N Y Acad Sci 2002;965:421–433.Google Scholar
Schifano, F, Oyefeso, A, Corkery, J, et al. Death rates from ecstasy (MDMA, MDA) and polydrug use in England and Wales 1996–2002. Hum Psychopharmacol Clin Exp 2003;18:519–524.Google Scholar
McGaw, C, Kankam, O. The co-ingestion of alcohol and mephedrone – an emerging cause of acute medical admissions in young adults and a potential cause of tachyarrhythmias. West London Med J 2010;2:9–13.Google Scholar
Angoa-Perez, M, Kane, M, Briggs, D, et al. Mephedrone does not damage dopamine nerve endings of the striatum, but enhances the neurotoxicity of methamphetamine, amphetamine and MDMA. J Neurochem 2013;125:102–110.Google Scholar
Aromatario, M, Bottoni, E, Santoni, M, Ciallella, C. New ‘lethal highs’: a case of a deadly cocktail of GHB and mephedrone. Forensic Sci Int 2012;223(1–3):e38–e41.Google Scholar
Potocka-Banas B, Janus T, Majdanik S, Banas T, Dembinska T, Borowiak K. Fatal intoxication with a-PVP, a synthetic cathinone derivative. J Forensic Sci 2016 (online). https://doi.org/10.1111/1556-4029.13326Google Scholar
Zaami, S, Giorgetti R, , Pichini S, , Pantano F, , Marinelli E, , Busardò, FP. Synthetic cathinones related fatalities: an update. Eur Rev Med Pharmacol Sci 2018;22:268–274.Google Scholar
European Monitoring Centre for Drugs and Drug Addiction. Annex 2. Technical Report on 1-(1,3-benzodioxol-5-yl)-2-(pyrrolidin-1-yl)pentan-1-one (3,4-methylenedioxypyrovalerone, MDPV). Prepared by Ms Alison M Dines, Dr David M Wood and Dr Paul I Dargan.Google Scholar
Potocka-Banas B, Janus T, Majdanik S, Banas T, Dembinska T, Borowiak K. Fatal intoxication with a-PVP, a synthetic cathinone derivative. J Forensic Sci 2016 (online). https://doi.org/10.1111/1556-4029.13326Google Scholar
Ikeji C, Sittambalam CD, Camire LM, Weisman DS. Fatal intoxication with N-ethylpentylone: a case report. J Community Hosp Int Med Perspect 2018;8(5):307–310. doi.org/10.1080/20009666.2018.1510711Google Scholar
Majchrzak M, Celiński R, Kowalska T, Sajewicz M. Fatal case of poisoning with a new cathinone derivative: α-propylaminopentiophenone (N-PP). Forensic Toxicol 2018;36(2):525–533. doi.org/10.1007/s11419-018-0417-xCrossRefGoogle Scholar
Atherton D, Dye D, Robinson CA, Beck R. n-Ethyl pentylone-related deaths in Alabama. J Forensic Sci 2019;64(1);304–308. doi.org/10.1111/1556-4029.13823Google Scholar
Pieprzyca E, Skowronek R, Korczyńska M, Kulikowska J, Chowaniec MA. Two fatal cases of poisoning involving new cathinone derivative PV8. Leg Med 2018;33;42–47. doi.org/10.1016/j.legalmed.2018.05.002Google Scholar
Sykutera M, , Cychowska M, , Bloch-Boguslawska E. A fatal case of pentedrone and a-pyrrolidinovalerophenone poisoning. Anal Toxicol 2015;39:324–329. https://doi.org/10.1093/jat/bkv011Google Scholar
Shah, AD, Wood, DM, Dargan, PI. Survey of ICD-10 coding of hospital admissions in the UK due to recreational drug toxicity. QJM 2011;104(9):779–784. https://doi.org/10.1093/qjmed/hcr074Google Scholar
Regan, L, Mitchelson, M, Macdonald, C. Mephedrone toxicity in a Scottish emergency department. Emerg Med J 2011;28:1055–1058.Google Scholar
Atreya RV, Sun J, Zhao Z. Exploring drug‐target interaction networks of illicit drugs. BMC Genom 2013;14(Suppl. 4):S1. https://doi. org/10.1186/1471‐2164‐14‐S4‐S1Google Scholar
Spiller, HA, Ryan, ML, Weston, RG, Jansen, J. Clinical experience with and analytical confirmation of ‘bath salts’ and ‘legal highs’ (synthetic cathinones) in the United States. Clin Toxicol 2011;49(6):499–505. https://doi.org/10.3109/15563650.2011.590812Google Scholar
Woo, TM, Hanley, J. ‘How do they look?’ Identification and treatment of common ingestions in adolescents. J Pediatr Health Care 2013;27(2):135–144. https://doi.org/10.1016/j.pedhc.2012.12.002Google Scholar
Beck O, , Franzen L, , Bäckberg M, , Signell, P, Helander, A. Intoxications involving MDPV in Sweden during 2010–2014: results from the STRIDA project. Clin Toxicol 2015;53(9):865–873. https://doi.org/10.3109/15563650.2015.1089576Google Scholar
Baumann, MH, Ayestas, MA Jr, Partilla, JS, et al. The designer methcathinone analogs, mephedrone and methylone, are substrates for monoamine transporters in brain tissue. Neuropsychopharmacology 2012;37(5):1192–1203. https://doi.org/10.1038/npp.2011.304Google Scholar
Bajaj, N, Mullen, D, Wylie, S. Dependence and psychosis with 4-methylmethcathinone (mephedrone) use. BMJ Case Rep 2010;2010:bcr0220102780. https://doi.org/10.1136/bcr.02.2010.2780Google Scholar
Simmler, LD, Buser, TA, Donzelli, M, et al. Pharmacological characterization of designer cathinones in vitro. Br J Pharmacol 2013;168 :458–470.Google Scholar
European Monitoring Centre for Drugs and Drug Addiction. Annex 2. Technical Report on 1-(1,3-benzodioxol-5-yl)-2-(pyrrolidin-1-yl)pentan-1-one (3,4-methylenedioxypyrovalerone, MDPV). Prepared by Ms Alison M Dines, Dr David M Wood and Dr Paul I Dargan.Google Scholar
Antonowicz, JL, Metzger, AK, Ramanujam, SL. Paranoid psychosis induced by consumption of methylenedioxypyrovalerone: two cases. Gen Hosp Psych 2011;33(640):e5.Google Scholar
Boulanger-Gobeil, C, St-Onge, M, Laliberte, M, Auger, PL. Seizures and hyponatremia related to ethcathinone and methylone poisoning. J Med Toxicol 2012;8(1):59–61.Google Scholar
European Monitoring Centre for Drugs and Drug Addiction. Drug profiles. Synthetic cathinones, 2012. Available at: www.emcdda.europa.eu/publications/drug-profiles/synthetic-cathinones_en [last accessed 18 March 2022].Google Scholar
Derungs, A, Schietzel, S, Meyer, MR, Maurer, HH, Kr€ahenb€uhl, S, Liechti, ME. Sympathomimetic toxicity in a case of analytically confirmed recreational use of naphyrone (naphthylpyrovalerone). Clin Toxicol 2011;49(7):691–693.Google Scholar
Winder, GS, Stern, N, Are, Hosanagar A. ‘bath salts’ the next generation of stimulant abuse? J Subst Abuse Treat 2013;44(1):42–45.Google Scholar
Spiller, HA, Ryan, ML, Weston, RG, Jansen, J. Clinical experience with and analytical confirmation of ‘bath salts’ and ‘legal highs’ (synthetic cathinones) in the United States. Clin Toxicol 2011;49(6):499–505.Google Scholar
Centers for Disease Control and Prevention (CDC). Emergency department visits after use of a drug sold as bath salts – Michigan, November 13, 2010 to March 31, 2011. Morb Mort Wkly Rep 2011;60(19):624–627.Google Scholar
Zawilska, JB, Słomiak, K, Wasiak, M, et al. Beta-cathinone derivatives – a new generation of dangerous psychostimulant ‘designer drugs’. Przegl Lek 2013;70(6):386–391.Google Scholar
Kelly, JP. Cathinone derivatives: a review of their chemistry, pharmacology and toxicology. Drug Test Anal 2011;3(7–8):43953.Google Scholar
Thornton, SL, Gerona, RR, Tomaszewski, CA. Psychosis from a bath salt product containing flephedrone and MDPV with serum, urine, and product quantification. J Med Toxicol 2012;8(3):310–313.Google Scholar
European Monitoring Centre for Drugs and Drug Addiction. Report on the risk assessment of 1-phenyl-2-(pyrrolidin-1-yl)pentan-1-one (αpyrrolidinovalerophenone, α-PVP). Luxembourg, Publications Office of the European Union, 2016. https://doi.org/10.2810/71700. ISBN 978-92-9168-931-6. Available at: www.emcdda.europa.eu/system/files/publications/2934/TDAK16001ENN.pdf[last accessed 18 March 2022].Google Scholar
International Classification of Disorders (ICD-11). Synthetic cathinone dependence. Available at: https://icd.who.int/browse11/l-m/en#http%3a%2f%2fid.who.int%2ficd%2fentity%2f2070676103 [last accessed 18 March 2022].Google Scholar
Hill, SL, Thomas, SH. Clinical toxicology of newer recreational drugs. Clin Toxicol 2011;49:705–719.Google Scholar
Sande M. Characteristics of the use of 3-MMC and other new psychoactive drugs in Slovenia, and the perceived problems experienced by users. Int J Drug Policy 2016;27:65–73.Google Scholar
Winstock, A, Mitcheson, L, Ramsey, J, Davies, S, Puchnarewics, M, Marsden, J. Mephedrone: subjective effects and health risks. Addiction 2011;106:1991–1996.Google Scholar
Corkery, JM, Guirguis, A, Papanti, DG, Orsolini, L, Schifano, F. Synthetic cathinones: prevalence and motivations for use. In: Zawilska, J (ed.), Synthetic Cathinones. Current Topics in Neurotoxicity, vol. 12. Cham, Springer. https://doi.org/10.1007/978-3-319-78707-7_9Google Scholar
Van Hout, MC. An internet study of user’s experiences of the synthetic cathinone 4- methylethcathinone (4-MEC). J Psychoactive Drugs 2014;46(4):273–286. https://doi.org/10.1080/02791072.2014.934979Google Scholar
Winder, GS, Stern, N, Hosanagar, A. Are ‘bath salts’ the next generation of stimulant abuse? J Subst Abuse Treat 2013;44(1):42–45. https://doi.org/10.1016/j.jsat.2012.02.003Google Scholar
Coppola, M, Mondola, R. Synthetic cathinones: chemistry, pharmacology and toxicology of a new class of designer drugs of abuse marketed as ‘bath salts’ or ‘plant food’. Toxicol Lett 2012;211(2):144–149. https://doi.org/10.1016/j.toxlet.2012.03.009Google Scholar
Lev-Ran, S. A case of treating cathinone dependence and comorbid depression using bupropion. J Psychoactive Drugs. 2012;44(5):434–436.Google Scholar
Antonowicz, JL, Metzger, AK, Ramanujam, SL. Paranoid psychosis induced by consumption of methylenedioxypyrovalerone: two cases. Gen Hosp Psychiatry 2011;33(6):640.e5–6. https://doi.org/10.1016/j.genhosppsych.2011.04.010Google Scholar
Sande M, , Paš M, , Nahtigal K, , Šabić S., Patterns of NPS use and risk reduction in Slovenia. Subst Use Misuse 2018;53(9):1424–1432. doi.org/10.1080/10826084.2017.1411366Google Scholar
Burch, HJ, Clarke, EJ, Hubbard, AM, Scott-Ham, M. Concentrations of drugs determined in blood samples collected from suspected drugged drivers in England and Wales. J Forensic Leg Med 2013;20(4):278–289. https://doi.org/10.1016/j.jflm.2012.10.005Google Scholar